Published • loading... • Updated
MSD Launches Pulmonary Arterial Hypertension Visibility Campaign
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pulmonary Arterial Hypertension (PAH) is one of the most serious forms of the five classes of Pulmonary Hypertension (HP) recognized by the World Health Organization (WHO). Although therapeutic advances have been made in recent years, PAH continues to face important challenges in its diagnosis, treatment and management. In the framework of World Pulmonary Hypertension Day, which is commemorated today, May 5, the biopharmaceutical company MSD rea…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
